EMA/660338/2020

European Medicines Agency decision

P/0517/2020

of 2 January 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for etranacogene dezaparvovec (EMEA-002722-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0517/2020

of 2 January 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for etranacogene dezaparvovec (EMEA-002722-PIP01-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by uniQure biopharma B.V. on 19 December 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 November 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for etranacogene dezaparvovec, solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for etranacogene dezaparvovec, solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to uniQure biopharma B.V., Paasheuvelweg 25A, 1105 BP - Amsterdam, Netherlands.

EMA/PDCO/446807/2020
Amsterdam, 13 November 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-002722-PIP01-19

Scope of the application

Active substance(s):

Etranacogene dezaparvovec

Condition(s):

Treatment of haemophilia B

Pharmaceutical form(s):

Solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

uniQure biopharma B.V.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, uniQure biopharma B.V. submitted for agreement to the European Medicines Agency on 19 December 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 28 January 2020.

Supplementary information was provided by the applicant on 7 August 2020. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of haemophilia B

2.1.1. Indication(s) targeted by the PIP

Prevention of bleeding in male haemophilia patients without history of Factor IX inhibitors and currently on stable FIX prophylaxis therapy

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	None.	Not applicable.
Non-clinical studies	3	**Study 1** Juvenile animal efficacy study in non-human primates (NHP) matching 12-year old children in age. **Study 2** Juvenile animal efficacy study in non-human primates (NHP) matching 4- to 6-year old children in age. **Study 3** Exploratory efficacy and toxicity study in very young pigs.
Clinical studies	3	**Study 4** Single dose, open-label study to evaluate the efficacy and safety of etranacogene dezaparvovec in patients from 12 years to less than 18 years of age with haemophilia B. **Study 5** Randomised study to evaluate the efficacy and safety of 2 dose levels

		of etranacogene dezaparvovec in children from 4 years to less than 12 years of age with haemophilia B. **Study 6** Open label study to evaluate the efficacy and safety of 2 dose levels of etranacogene dezaparvovec in children from birth to less than 4 years of age with haemophilia B.
Extrapolation, modelling and simulation studies	None.	Not applicable.
Other studies	None.	Not applicable.
Other measures	None.	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2042
Deferral for one or more measures contained in the paediatric investigation plan:	Yes